PR97247

NEWARK, Del., July 28, 2022 /PRNewswire=KYODO JBN/ --

ILC Dover LP ("ILC Dover" or the "Company"), specializing in innovative

single-use solutions for biotherapeutics and pharmaceutical processing,

announced the launch of Water for Injection (WFI) for the biotherapeutics

market. Used for the preparation of media, buffers, and other ingredients for

biopharmaceuticals and medical devices, this launch continues to expand ILC

Dover's integrated solution set across the entire biotherapeutic and

pharmaceutical manufacturing workflow.

The addition of WFI follows new product offerings including single-use liquid

bags in addition to the Company's most recent acquisition of KSE Scientific in

December 2021. As a leading supplier of WFI and related solutions for emerging

biopharma, cell & gene therapy, tissue banking and medical device end markets,

KSE Scientific with ILC Dover combined decades of world-class engineering to

offer synergies across the liquid handling and transfer workflows to meet

customers' most challenging specs and end uses.

The Company will manufacture multi-compendial WFI solutions in Durham, NC but

ultimately will utilize its growing cGMP global footprint to support its

customers and partners worldwide.

"When we identify constraints in the markets we serve – we respond. Now, by

securing supply and strengthening our reliability as a solutions provider, ILC

Dover is in a position to offer WFI and single-use liquid bags to customers

across the world," said Corey Walker, CEO of ILC Dover. "As we continue to grow

and meet demand, we will remain focused on providing broader and more

integrated workflow solutions within the biopharma, cell & gene therapy, and

related life sciences end markets."

In addition, the Company embarked upon an expansion project within KSE

Scientific's 25,000 sq ft production facility in Durham, NC to offer WFI

produced by distillation, a key raw material for the biopharma and cell & gene

therapy markets. This expansion allows ILC Dover to have greater flexibility in

serving customers around the world by adding distillation for WFI to existing

reverse osmosis WFI capabilities. In-house capability to produce WFI by

distillation was a critical milestone for ILC Dover's rapid expansion into

other sterile liquids offerings coming soon.

ILC Dover is committed to providing comprehensive solutions customized to its

customers' unique needs. With the recent launches of its in-house manufactured

liquid bags, fluid transfer assemblies, and WFI, ILC Dover can now offer

customized WFI solutions with a resilient supply chain, unparalleled delivery

times, and rapid scalability.

To learn more about ILC Dover's WFI and cGMP chemicals solutions, please visit

https://www.ilcdover.com/products/water-for-injection-wfi-quality-water/ or

contact your local sales representative.

SOURCE  ILC Dover, Inc.

CONTACT: Mike Mills, mikem@sagefrog.com